Compare Vertex Pharmaceuticals Incorporated (VRTX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs TeraWulf Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B), while TeraWulf Inc trades at $13.86 (market cap $6.81B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.7× TeraWulf Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and TeraWulf Inc for 17 Days on average.
| VRTX | WULF | |
|---|---|---|
Market Cap | $127.55B | $6.81B |
Volume | 1,487,944 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $557.96 | $28.98 |
52-Week Low | $407.37 | $10.99 |
Typical Hold Time | 120 Days | 17 Days |
Enterprise Value | $121.68B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
WULF trades at $14.40, down 3.81% on the day, with a bearish technical signal from moving averages and oscillators showing mixed signals. The company reported a net loss of -$661.42M in 2025, with revenue of $168.46M, and has missed earnings expectations in recent quarters. Analyst consensus remains strongly bullish with a $34.92 price target, supported by positive news on AI data center leasing trends.
The outlook for WULF hinges on its pivot to AI data center hosting, offering growth potential, but significant risks persist from deep losses, negative margins, and high debt. Investors should weigh analyst optimism against fundamental weaknesses and volatile cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
